Quantitative results shown in Figure 8 indicate that only the treatment with administration of both RevTM CEA-IgG4-7B6 and RevTM EpCAM-IgG1-5B9 inhibits tumor growth compared to the control group that received HT-29 CEAHIGH Luc+ together with Dual-RevCAR T-cells. Here, CEACAM5 is linked to neoplasm.